Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Mehr Informationen
Referenzen
Diskussion
Dateien

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy - RWTH-CONV-250008

Main document Datei(en):

Ähnliche Datensätze

h1

h2

h3

h4

h5

h6

RWTH

Kontakt

RWTH Publications

Allgemeines